Tevimbra Injection, Solution, Concentrate
NDC 72579-121
Product Information
Tevimbra (tislelizumab-jsgr) is a BLA-approved product labeled by Beone Medicines Usa, Inc.. This medication is typically used as a programmed death receptor-1 blocking antibody [epc]. It is supplied as a injection, solution, concentrate for intravenous administration. This product entry covers the primary NDC 72579-121 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 72579-121?
What are the uses of this product?
What are Active Ingredients of this product?
- TISLELIZUMAB 10 mg/mL - a humanized anti-PD-1 monoclonal antibody
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TISLELIZUMAB (UNII: 0KVO411B3N)
- TISLELIZUMAB (UNII: 0KVO411B3N) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- HISTIDINE (UNII: 4QD397987E)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- SODIUM CITRATE, UNSPECIFIED FORM (UNII: 1Q73Q2JULR)
- TREHALOSE (UNII: B8WCK70T7I)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2677432 - tislelizumab-jsgr 100 MG in 10 ML Injection
- RxCUI: 2677432 - 10 ML tislelizumab-jsgr 10 MG/ML Injection
- RxCUI: 2677432 - tislelizumab-jsgr 100 MG per 10 ML Injection
- RxCUI: 2677439 - TEVIMBRA 100 MG in 10 ML Injection
- RxCUI: 2677439 - 10 ML tislelizumab-jsgr 10 MG/ML Injection [Tevimbra]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.